Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13810)
All Articles published online
|
Publishing Process of This Article
|
Jan 7, 2017 (publication date) through Jan 30, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol 2017; 23(1): 141-150 [PMID: 28104990 DOI: 10.3748/wjg.v23.i1.141] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i1/141.htm |
| Number | Citing Articles |
| 1 |
Emily Brown, T. Hydes, A. Hamid, D.J. Cuthbertson. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clinical Therapeutics 2021; 43(9): 1476 doi: 10.1016/j.clinthera.2021.07.013
|
| 2 |
Rashmi Pathak, Avinash Kumar, Henry A. Palfrey, Kirsten P. Stone, Narayan R. Raju, Thomas W. Gettys, Subramanyam N. Murthy. Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague–Dawley rats fed a high-cholesterol diet. Inflammation Research 2022; 71(5-6): 711 doi: 10.1007/s00011-022-01572-4
|
| 3 |
Agostino Di Ciaula, Salvatore Passarella, Harshitha Shanmugam, Marica Noviello, Leonilde Bonfrate, David Q.-H. Wang, Piero Portincasa. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. International Journal of Molecular Sciences 2021; 22(10): 5375 doi: 10.3390/ijms22105375
|
| 4 |
Jeffrey Budd, Kenneth Cusi. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Current Diabetes Reports 2020; 20(11) doi: 10.1007/s11892-020-01349-1
|
| 5 |
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, Michael Roden. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nature Reviews Gastroenterology & Hepatology 2021; 18(9): 599 doi: 10.1038/s41575-021-00448-y
|
| 6 |
Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong. Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials. Obesity Reviews 2024; 25(6) doi: 10.1111/obr.13727
|
| 7 |
Da Zhou, Jiangao Fan. Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction. Chinese Medical Journal 2024; 137(22): 2687 doi: 10.1097/CM9.0000000000003355
|
| 8 |
Hirofumi Okubo, Akifumi Kushiyama, Yusuke Nakatsu, Takeshi Yamamotoya, Yasuka Matsunaga, Midori Fujishiro, Hideyuki Sakoda, Haruya Ohno, Masayasu Yoneda, Tomoichiro Asano. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. International Journal of Molecular Sciences 2018; 19(10): 3064 doi: 10.3390/ijms19103064
|
| 9 |
Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez. Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica. Gastroenterología y Hepatología 2018; 41(2): 128 doi: 10.1016/j.gastrohep.2017.07.006
|
| 10 |
Jörg Bojunga. Diabetestherapie bei nichtalkoholischer Fettlebererkrankung und Leberzirrhose. Der Gastroenterologe 2020; 15(2): 96 doi: 10.1007/s11377-020-00417-y
|
| 11 |
Amalia Gastaldelli, Norbert Stefan, Hans-Ulrich Häring. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021; 64(7): 1461 doi: 10.1007/s00125-021-05442-2
|
| 12 |
Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun Takyar, Yaron Rotman, Ohad Etzion, Eric Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop, Mohammad Hassan Murad, Mazen Noureddin. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2019; 17(4): 616 doi: 10.1016/j.cgh.2018.06.011
|
| 13 |
Daniel Ferguson, Brian N. Finck. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology 2021; 17(8): 484 doi: 10.1038/s41574-021-00507-z
|
| 14 |
Lingling Ding, Yvonne Oligschlaeger, Ronit Shiri-Sverdlov, Tom Houben. Prevention and Treatment of Atherosclerosis. Handbook of Experimental Pharmacology 2020; 270: 233 doi: 10.1007/164_2020_352
|
| 15 |
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. Metabolism 2019; 101: 154001 doi: 10.1016/j.metabol.2019.154001
|
| 16 |
Kenneth Cusi, Scott Isaacs, Diana Barb, Rita Basu, Sonia Caprio, W. Timothy Garvey, Sangeeta Kashyap, Jeffrey I. Mechanick, Marialena Mouzaki, Karl Nadolsky, Mary E. Rinella, Miriam B. Vos, Zobair Younossi. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocrine Practice 2022; 28(5): 528 doi: 10.1016/j.eprac.2022.03.010
|
| 17 |
Robert Gish, Jian-Gao Fan, Zahra Dossaji, Jeanne Fichez, Tooba Laeeq, Magnus Chun, Jerome Boursier. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease. Hepatology International 2024; 18(S2): 977 doi: 10.1007/s12072-024-10698-y
|
| 18 |
Fernando Bril, Gabriela Berg, Magali Barchuk, Juan Patricio Nogueira. Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Lipid and Atherosclerosis 2025; 14(1): 5 doi: 10.12997/jla.2025.14.1.5
|
| 19 |
Kalliopi Pafili, Michael Roden. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Molecular Metabolism 2021; 50: 101122 doi: 10.1016/j.molmet.2020.101122
|
| 20 |
Maria Apostolopoulou, Michael Roden. Nicht-alkoholische Fettlebererkrankung. 2022; : 211 doi: 10.1007/978-3-662-62484-5_20
|
| 21 |
Rosann Cholankeril, Vikram Patel, Brandon J. Perumpail, Eric R. Yoo, Umair Iqbal, Sandy Sallam, Neha D. Shah, Waiyee Kwong, Donghee Kim, Aijaz Ahmed. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases 2018; 6(4): 93 doi: 10.3390/diseases6040093
|
| 22 |
Sofiya Gancheva, Michael Roden, Laurent Castera. Diabetes as a risk factor for MASH progression. Diabetes Research and Clinical Practice 2024; 217: 111846 doi: 10.1016/j.diabres.2024.111846
|
| 23 |
Yali Qu, Mou Li, Gavin Hamilton, Yingzhen N. Zhang, Bin Song. Diagnostic accuracy of hepatic proton density fat fraction measured by magnetic resonance imaging for the evaluation of liver steatosis with histology as reference standard: a meta-analysis. European Radiology 2019; 29(10): 5180 doi: 10.1007/s00330-019-06071-5
|
| 24 |
Iben Rix, Julie Steen Pedersen, Heidi Storgaard, Lise Lotte Gluud. Cardiometabolic effects of antidiabetic drugs in non‐alcoholic fatty liver disease. Clinical Physiology and Functional Imaging 2019; 39(2): 122 doi: 10.1111/cpf.12526
|
| 25 |
Jeff Y. Yang, Andrew M. Moon, Hannah Kim, Virginia Pate, A. Sidney Barritt, Matthew J. Crowley, John B. Buse, Til Stürmer, Anastasia-Stefania Alexopoulos. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. Journal of Diabetes and its Complications 2020; 34(11): 107706 doi: 10.1016/j.jdiacomp.2020.107706
|
| 26 |
Abdulrahman Ismaiel, Dan L. Dumitrascu. How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease. American Journal of Therapeutics 2023; 30(3): e242 doi: 10.1097/MJT.0000000000001174
|
| 27 |
Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi, Theodoros Androutsakos. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. European Journal of Clinical Pharmacology 2024; 80(1): 127 doi: 10.1007/s00228-023-03586-1
|
| 28 |
Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani. A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.937554
|
| 29 |
Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola, Salvatore Petta. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals 2018; 11(4): 121 doi: 10.3390/ph11040121
|
| 30 |
Minyoung Lee, Eugene Shin, Jaehyun Bae, Yongin Cho, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-75288-y
|
| 31 |
Sarra Smati, Clémence M Canivet, Jérôme Boursier, Bertrand Cariou. Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert Opinion on Investigational Drugs 2021; 30(8): 813 doi: 10.1080/13543784.2021.1951701
|
| 32 |
Cai-yan Zou, Yan Sun, Jun Liang. Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,,. Clinics and Research in Hepatology and Gastroenterology 2023; 47(1): 102053 doi: 10.1016/j.clinre.2022.102053
|
| 33 |
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology 2021; 27(2): 221 doi: 10.3350/cmh.2020.0239
|
| 34 |
Cheng Han Ng, Jieling Xiao, Wen Hui Lim, Yip Han Chin, Jie Ning Yong, Darren Jun Hao Tan, Phoebe Tay, Nicholas Syn, Roger Foo, Mark Chan, Nicholas Chew, Eunice XX Tan, Daniel Q. Huang, Yock Young Dan, Nobuharu Tamaki, Mohammad Shadab Siddiqui, Arun J. Sanyal, Rohit Loomba, Mazen Noureddin, Mark D. Muthiah. Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis. Hepatology 2022; 75(6): 1647 doi: 10.1002/hep.32315
|
| 35 |
Sabine Kahl, Jennifer Pützer, Michael Roden. Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Seminars in Liver Disease 2022; 42(01): 048 doi: 10.1055/s-0041-1732354
|
| 36 |
Yong Kyun Cho. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?. Clinical and Molecular Hepatology 2018; 24(3): 299 doi: 10.3350/cmh.2018.1006
|
| 37 |
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, Terry D. Hinds, David E. Stec. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clinical Science 2022; 136(18): 1347 doi: 10.1042/CS20220572
|
| 38 |
Daisuke Kaya, Kosuke Kaji, Yuki Tsuji, Satoko Yamashita, Koh Kitagawa, Takahiro Ozutsumi, Yukihisa Fujinaga, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. Cells 2019; 8(10): 1153 doi: 10.3390/cells8101153
|
| 39 |
Iryna Kostitska, Nadia Protas, Liliia Petrovska. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD). Diabetes Obesity Metabolic Syndrome 2023; (5): 8 doi: 10.57105/2415-7252-2023-5-01
|
| 40 |
Anca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, Dragana Nikolic, Angelo Maria Patti, Ali A. Rizvi. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism 2020; 109: 154295 doi: 10.1016/j.metabol.2020.154295
|
| 41 |
L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. Frontiers in Endocrinology 2020; 11 doi: 10.3389/fendo.2020.597583
|
| 42 |
Kyung-Soo Kim, Byung-Wan Lee. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clinical and Molecular Hepatology 2020; 26(4): 430 doi: 10.3350/cmh.2020.0137
|
| 43 |
Fernando Bril, Gabriela Berg, Magali Barchuk, Juan Patricio Nogueira. Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Lipid and Atherosclerosis 2025; 14(1): 69 doi: 10.12997/jla.2025.14.1.69
|
| 44 |
Jörg Bojunga, Gesine Meyer, Antonia Mondorf. Das Leben und das Essen trotz nichtalkoholischer Fettleber genießen. Info Diabetologie 2019; 13(4): 30 doi: 10.1007/s15034-019-1527-1
|
| 45 |
Naotaka Shimozato, Tadashi Namisaki, Kosuke Kaji, Mitsuteru Kitade, Yasushi Okura, Shinya Sato, Kei Moriya, Kenichiro Seki, Hideto Kawaratani, Hiroaki Takaya, Yasuhiko Sawada, Soichiro Saikawa, Keisuke Nakanishi, Masanori Furukawa, Yukihisa Fujinaga, Takuya Kubo, Kiyoshi Asada, Koh Kitagawa, Yuki Tsuji, Daisuke Kaya, Takahiro Ozutsumi, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis. Hepatology Research 2019; 49(10): 1147 doi: 10.1111/hepr.13385
|
| 46 |
Ignazio Grattagliano, Agostino Di Ciaula, Jacek Baj, Emilio Molina-Molina, Harshitha Shanmugam, Gabriella Garruti, David Q. -H. Wang, Piero Portincasa. Mitochondrial Regulation. Methods in Molecular Biology 2021; 2310: 201 doi: 10.1007/978-1-0716-1433-4_12
|
| 47 |
Shendong Wang, Junhao Yin, Zhaojun Liu, Xin Liu, Ge Tian, Xijian Xin, Yiming Qin, Xiujing Feng. Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease. Life Sciences 2024; 359: 123211 doi: 10.1016/j.lfs.2024.123211
|
| 48 |
Gebran Khneizer, Syed Rizvi, Samer Gawrieh. Diabetes: from Research to Clinical Practice. Advances in Experimental Medicine and Biology 2020; 1307: 417 doi: 10.1007/5584_2020_532
|
| 49 |
Haiyan Zhou, Maeda Toshiyoshi,, Wenli Zhao, Ye Zhao, Yan Zhao. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine 2023; 102(26): e33981 doi: 10.1097/MD.0000000000033981
|
| 50 |
Sven M. Francque, Giulio Marchesini, Achim Kautz, Martine Walmsley, Rebecca Dorner, Jeffrey V. Lazarus, Shira Zelber-Sagi, Kate Hallsworth, Luca Busetto, Gema Frühbeck, Dror Dicker, Euan Woodward, Marko Korenjak, José Willemse, Gerardus H. Koek, Shlomo Vinker, Mehmet Ungan, Juan M. Mendive, Christos Lionis. Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports 2021; 3(5): 100322 doi: 10.1016/j.jhepr.2021.100322
|
| 51 |
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh. Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1150360
|
| 52 |
Mary E. Rinella, Brent A. Neuschwander-Tetri, Mohammad Shadab Siddiqui, Manal F. Abdelmalek, Stephen Caldwell, Diana Barb, David E. Kleiner, Rohit Loomba. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77(5): 1797 doi: 10.1097/HEP.0000000000000323
|
| 53 |
Satoshi Shinozaki, Toshiyuki Tahara, Kouichi Miura, Alan Kawarai Lefor, Hironori Yamamoto. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study. Life 2023; 13(6): 1327 doi: 10.3390/life13061327
|
| 54 |
Rebecca K. Vincent, David M. Williams, Marc Evans. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?. Diabetes, Obesity and Metabolism 2020; 22(12): 2227 doi: 10.1111/dom.14196
|
| 55 |
Youngmi Song, Hyekyung Yang, Juhee Kim, Yoonjin Lee, Sung-Ho Kim, In-Gu Do, Cheol-Young Park. Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy. Molecular Metabolism 2023; 78: 101806 doi: 10.1016/j.molmet.2023.101806
|
| 56 |
Leslye Sámano-Hernández, Reyna Fierro, Aude Marchal, Jean-Louis Guéant, Humberto González-Márquez, Rosa-María Guéant-Rodríguez. Beneficial and deleterious effects of sitagliptin on a methionine/choline-deficient diet-induced steatohepatitis in rats. Biochimie 2021; 181: 240 doi: 10.1016/j.biochi.2020.12.004
|
| 57 |
Carolyn F. Deacon. A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials. Diabetes, Obesity and Metabolism 2018; 20(S1): 34 doi: 10.1111/dom.13135
|
| 58 |
Georgia Anastasiou, Konstantinos Stefanakis, Michael A. Hill, Christos S. Mantzoros. Expanding diagnostic and therapeutic horizons for MASH: Comparison of the latest and conventional therapeutic approaches. Metabolism 2024; 161: 156044 doi: 10.1016/j.metabol.2024.156044
|
| 59 |
Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas, Christos S. Mantzoros. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology 2020; 18(2): 172 doi: 10.2174/1570161117666190405164313
|
| 60 |
Waihong Chung, Kittichai Promrat, Jack Wands. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World Journal of Hepatology 2020; 12(9): 533-557 doi: 10.4254/wjh.v12.i9.533
|
| 61 |
Luca Maroni, Francesca Fianchi, Luca Miele, Gianluca Svegliati Baroni. The Complex Interplay Between Gut-Brain, Gut-Liver, and Liver-Brain Axes. 2021; : 97 doi: 10.1016/B978-0-12-821927-0.00002-4
|
| 62 |
Tianyu Mao, Yiwen Sun, Xinyi Xu, Kang He. Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention. Hepatology Communications 2023; 7(10) doi: 10.1097/HC9.0000000000000234
|
| 63 |
Sven Francque, Luisa Vonghia. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. Advances in Therapy 2019; 36(5): 1052 doi: 10.1007/s12325-019-00898-6
|
| 64 |
Alexander J. Kovalic, Sanjaya K. Satapathy, Naga Chalasani. Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. Hepatology International 2018; 12(2): 97 doi: 10.1007/s12072-018-9854-1
|
| 65 |
Zeynep Melekoglu Ellik. Current Perspective on Diabetes Mellitus in Clinical Sciences. 2023; : 399 doi: 10.69860/nobel.9786053359111.37
|
| 66 |
Heather S. Snyder, Sami A. Sakaan, Katherine L. March, Osama Siddique, Rosann Cholankeril, Carolyn D. Cummings, Chiran Gadiparthi, Sanjaya K. Satapathy, Aijaz Ahmed, George Cholankeril. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. Journal of Clinical and Translational Hepatology 2018; 6(2): 1 doi: 10.14218/JCTH.2017.00050
|
| 67 |
Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez. New therapeutic perspectives in non-alcoholic steatohepatitis. Gastroenterología y Hepatología (English Edition) 2018; 41(2): 128 doi: 10.1016/j.gastre.2017.07.016
|
| 68 |
Kook Hwan Kim, Myung-Shik Lee. Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00485
|
| 69 |
Claire J. Grant, Trevor P. Wade, Charles A. McKenzie, Guido Filler, Christopher W. McIntyre, Shih-Han S. Huang. Effect of ultrafiltration during hemodialysis on hepatic and total-body water: an observational study. BMC Nephrology 2018; 19(1) doi: 10.1186/s12882-018-1150-8
|
| 70 |
Egeria Scoditti, Silvia Sabatini, Fabrizia Carli, Amalia Gastaldelli. Hepatic glucose metabolism in the steatotic liver. Nature Reviews Gastroenterology & Hepatology 2024; 21(5): 319 doi: 10.1038/s41575-023-00888-8
|
| 71 |
Xiaolong Qi, Jie Li, Cyrielle Caussy, Gao-Jun Teng, Rohit Loomba. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease. Hepatology 2024; doi: 10.1097/HEP.0000000000000913
|
| 72 |
Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden. Metabolic liver disease in diabetes – From mechanisms to clinical trials. Metabolism 2020; 111: 154299 doi: 10.1016/j.metabol.2020.154299
|
| 73 |
Georgios Tsamos, Dimitra Vasdeki, Theocharis Koufakis, Vassiliki Michou, Kali Makedou, Georgios Tzimagiorgis. Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes. Metabolites 2023; 13(4): 517 doi: 10.3390/metabo13040517
|
| 74 |
Jingxuan Lian, Jianfang Fu. Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.649018
|
| 75 |
Oliver Glass, Claudia Filozof, Mazen Noureddin, Mark Berner-Hansen, Elmer Schabel, Stephanie O. Omokaro, Jörn M. Schattenberg, Katherine Barradas, Veronica Miller, Sven Francque, Manal F. Abdelmalek. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. Journal of Hepatology 2020; 73(3): 680 doi: 10.1016/j.jhep.2020.04.030
|
| 76 |
Gianluca Svegliati-Baroni, Bárbara Patrício, Gessica Lioci, Maria Paula Macedo, Amalia Gastaldelli. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. International Journal of Molecular Sciences 2020; 21(16): 5820 doi: 10.3390/ijms21165820
|
| 77 |
Han Ah Lee, Hye Ah Lee, Hwi Young Kim. Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-79428-6
|
| 78 |
Yiduo Feng, Beibei Shang, Yu Yang, Donglei Zhang, Changbin Liu, Zheng Qin, Yilun Zhou, Jie Meng, Xin Liu. Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism 2024; doi: 10.1210/clinem/dgae783
|
| 79 |
Nahum Méndez-Sánchez, Shreya C. Pal, Jacqueline Córdova-Gallardo. How far are we from an approved drug for nonalcoholic steatohepatitis?. Expert Opinion on Pharmacotherapy 2023; 24(9): 1021 doi: 10.1080/14656566.2023.2206953
|
| 80 |
Amalia Gastaldelli, Kenneth Cusi. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports 2019; 1(4): 312 doi: 10.1016/j.jhepr.2019.07.002
|
| 81 |
Bertrand Cariou. The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes, Obesity and Metabolism 2022; 24(S2): 15 doi: 10.1111/dom.14651
|
| 82 |
John A. Dougherty, Erenie Guirguis, Krisy-Ann Thornby. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Annals of Pharmacotherapy 2021; 55(1): 65 doi: 10.1177/1060028020935105
|
| 83 |
Gea Ciccarelli, Gianfranco Di Giuseppe, Francesca Cinti, Simona Moffa, Teresa Mezza, Andrea Giaccari. Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis. Diabetes/Metabolism Research and Reviews 2023; 39(7) doi: 10.1002/dmrr.3668
|
| 84 |
Evangelia Makri, Marina Kita, Antonis Goulas, Paraskevi Papaioannidou, Zoe A. Efstathiadou, Fotini Adamidou, Stergios A. Polyzos. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2020; 14(6): 1913 doi: 10.1016/j.dsx.2020.09.030
|
| 85 |
Kenneth Cusi. Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. Hepatology 2019; 69(6): 2318 doi: 10.1002/hep.30670
|
| 86 |
Stergios A. Polyzos, Eun Seok Kang, Chrysoula Boutari, Eun-Jung Rhee, Christos S. Mantzoros. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020; 111: 154203 doi: 10.1016/j.metabol.2020.154203
|
| 87 |
Thomas Marjot, Ahmad Moolla, Jeremy F Cobbold, Leanne Hodson, Jeremy W Tomlinson. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews 2020; 41(1): 66 doi: 10.1210/endrev/bnz009
|
| 88 |
Gang Ma, Song Zhang, Baozhong Yu. Impact of Dipeptidyl Peptidase-4 Inhibitors on Aminotransferases Levels in Patients with Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trial. Current Therapeutic Research 2025; 102: 100768 doi: 10.1016/j.curtheres.2024.100768
|
| 89 |
Tanawan Kongmalai, Varalak Srinonprasert, Thunyarat Anothaisintawee, Pinkawas Kongmalai, Gareth McKay, John Attia, Ammarin Thakkinstian. New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1182037
|
| 90 |
André Jacques Scheen. The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety 2018; 17(4): 387 doi: 10.1080/14740338.2018.1444027
|
| 91 |
Konstantinos Malandris, Stylianos Papandreou, Despoina Vasilakou, Panagiota Kakotrichi, Anna Sarakapina, Georgios Kalopitas, Thomas Karagiannis, Olga Giouleme, Eleni Bekiari, Aris Liakos, Fotini Iatridi, Paschalis Paschos, Emmanouil Sinakos, Apostolos Tsapas. Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta‐analysis. Journal of Gastroenterology and Hepatology 2024; 39(7): 1219 doi: 10.1111/jgh.16559
|
| 92 |
Sanja Stojsavljevic-Shapeski, Marko Duvnjak, Lucija Virovic-Jukic, Davor Hrabar, Lea Smircic Duvnjak. New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis. Journal of Clinical and Translational Hepatology 2020; 0(000): 1 doi: 10.14218/JCTH.2020.00057
|
| 93 |
Jörg Bojunga, Mireen Friedrich-Rust. Diabetestherapie bei fortgeschrittenen Lebererkrankungen und Leberzirrhose. Der Diabetologe 2022; 18(1): 26 doi: 10.1007/s11428-021-00822-z
|
| 94 |
Yifan Wang, He Yi, Weixia Sun, Hekai Yu, Wenxuan Tao, Xiaojin Yu, Dianrong Jia, Yingzhao Liu, Stephen J. Pandol, Ling Li. Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials. Drugs 2024; 84(4): 425 doi: 10.1007/s40265-024-02015-6
|
| 95 |
Stefano Fiorucci, Michele Biagioli, Eleonora Distrutti. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacological Research 2018; 134: 289 doi: 10.1016/j.phrs.2018.07.014
|
| 96 |
Elodie M. Varin, Erin E. Mulvihill, Jacqueline L. Beaudry, Gemma Pujadas, Shai Fuchs, Jean-François Tanti, Sofia Fazio, Kirandeep Kaur, Xiemin Cao, Laurie L. Baggio, Dianne Matthews, Jonathan E. Campbell, Daniel J. Drucker. Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition. Cell Metabolism 2019; 29(2): 320 doi: 10.1016/j.cmet.2018.10.001
|
| 97 |
Laura Iogna Prat, Emmanuel A. Tsochatzis. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones 2018; 17(2): 219 doi: 10.1007/s42000-018-0021-9
|
| 98 |
Si-min Fan, Xiao-yan Shi, Yan-ping Fan, Lin-lin Yang, Jia Yao, Pei-min Feng. Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease. Medicine 2020; 99(27): e20695 doi: 10.1097/MD.0000000000020695
|
| 99 |
Ekaterina E. Mishina, Alexander Y. Mayorov, Pavel O. Bogomolov, Ekaterina O. Liusina, Alexey O. Bueverov. Association of insulin resistance and non-alcoholic fatty liver disease. Diabetes mellitus 2021; 23(5): 412 doi: 10.14341/DM12234
|
| 100 |
Luc F. Van Gaal, Jonathan Mertens, Sven Francque, Christophe De Block. Therapeutic approaches for non-alcoholic steatohepatitis. Therapeutic Advances in Endocrinology and Metabolism 2021; 12 doi: 10.1177/20420188211034300
|
| 101 |
Yaodi Shao, Suzhen Chen, Liu Han, Junli Liu. Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention. Nutrition & Metabolism 2023; 20(1) doi: 10.1186/s12986-023-00748-x
|
| 102 |
Paul P. Manka, Eda Kaya, Ali Canbay, Wing-Kin Syn. A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences 2021; 66(11): 3676 doi: 10.1007/s10620-021-07206-9
|
| 103 |
Hiroshi Tobita, Tomotaka Yazaki, Masatoshi Kataoka, Satoshi Kotani, Akihiko Oka, Tsuyoshi Mishiro, Naoki Oshima, Kousaku Kawashima, Norihisa Ishimura, Kohji Naora, Shuichi Sato, Shunji Ishihara. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. Journal of Clinical Biochemistry and Nutrition 2021; 68(2): 173 doi: 10.3164/jcbn.20-129
|
| 104 |
Danielle Alvares, Simon Hoffman, Bogdan Stankovic, Khosrow Adeli. Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019; 1864(3): 326 doi: 10.1016/j.bbalip.2018.12.010
|
| 105 |
Zuo-Di Fu, Xiao-Ling Cai, Wen-Jia Yang, Ming-Ming Zhao, Ran Li, Yu-Feng Li. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World Journal of Diabetes 2021; 12(1): 84-97 doi: 10.4239/wjd.v12.i1.84
|
| 106 |
Weijia Xie, Xiaoxiao Song, Zhenjie Liu. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascular Pharmacology 2018; 109: 17 doi: 10.1016/j.vph.2018.05.010
|
| 107 |
Kenneth Cusi. Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes. Diabetes Care 2020; 43(2): 275 doi: 10.2337/dci19-0064
|
| 108 |
Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants 2022; 11(6): 1060 doi: 10.3390/antiox11061060
|
| 109 |
Konstantinos Malandris, Stylianos Papandreou, Ioannis Avgerinos, Thomas Karagiannis, Paschalis Paschos, Theodoros Michailidis, Aris Liakos, Eleni Bekiari, Emmanouil Sinakos, Apostolos Tsapas. Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis. Hormones 2023; 22(4): 655 doi: 10.1007/s42000-023-00493-z
|
| 110 |
Ignazio Grattagliano, Liliana P. Montezinho, Paulo J. Oliveira, Gema Frühbeck, Javier Gómez-Ambrosi, Fabrizio Montecucco, Federico Carbone, Mariusz R. Wieckowski, David Q.-H. Wang, Piero Portincasa. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. Biochemical Pharmacology 2019; 160: 34 doi: 10.1016/j.bcp.2018.11.020
|
| 111 |
Takahiro Ozutsumi, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Yuki Tsuji, Daisuke Kaya, Yukihisa Fujinaga, Masanori Furukawa, Keisuke Nakanishi, Shinya Sato, Yasuhiko Sawada, Soichiro Saikawa, Koh Kitagawa, Hiroaki Takaya, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya, Ryuichi Noguchi, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. International Journal of Molecular Sciences 2020; 21(6): 2164 doi: 10.3390/ijms21062164
|
| 112 |
Jennifer Pützer, Sabine Kahl. Nichtalkoholische Fettlebererkrankung und Typ‑2‑Diabetes. Der Diabetologe 2020; 16(6): 574 doi: 10.1007/s11428-020-00649-0
|
| 113 |
Anna Veelen, Edmundo Erazo-Tapia, Jan Oscarsson, Patrick Schrauwen. Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?. Molecular Metabolism 2021; 46: 101158 doi: 10.1016/j.molmet.2020.101158
|
| 114 |
Yoshitaka Arase, Koichi Shiraishi, Kazuya Anzai, Hirohiko Sato, Erika Teramura, Kota Tsuruya, Shunji Hirose, Ryuzo Deguchi, Masao Toyoda, Tetsuya Mine, Tatehiro Kagawa. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clinical Drug Investigation 2019; 39(7): 631 doi: 10.1007/s40261-019-00785-6
|
| 115 |
Reenam S. Khan, Fernando Bril, Kenneth Cusi, Philip N. Newsome. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology 2019; 70(2): 711 doi: 10.1002/hep.30429
|
| 116 |
Giovanni Targher, Amedeo Lonardo, Christopher D. Byrne. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nature Reviews Endocrinology 2018; 14(2): 99 doi: 10.1038/nrendo.2017.173
|
| 117 |
Sukhpreet Singh, Natalia A Osna, Kusum K Kharbanda. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World Journal of Gastroenterology 2017; 23(36): 6549-6570 doi: 10.3748/wjg.v23.i36.6549
|
| 118 |
Cheng Han Ng, Mark D. Muthiah, Jieling Xiao, Yip Han Chin, Grace Lim, Wen Hui Lim, Phoebe Tay, Darren Jun Hao Tan, Jie Ning Yong, Xin‐Hui Pan, Jeffery Wei Heng Koh, Nicholas Chew, Nicholas Syn, Eunice Tan, Daniel Q. Huang, Mohammad Shadab Siddiqui, Rohit Loomba, Arun J. Sanyal, Mazen Noureddin. Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis. Alimentary Pharmacology & Therapeutics 2022; 55(9): 1076 doi: 10.1111/apt.16808
|
| 119 |
Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. Clinical and Molecular Hepatology 2022; 28(4): 725 doi: 10.3350/cmh.2022.0015
|
| 120 |
Samy El-Megharbel, Najah Al-Baqami, Eman Al-Thubaiti, Safa Qahl, Bander Albogami, Reham Hamza. Antidiabetic Drug Sitagliptin with Divalent Transition Metals Manganese and Cobalt: Synthesis, Structure, Characterization Antibacterial and Antioxidative Effects in Liver Tissues. Current Issues in Molecular Biology 2022; 44(5): 1810 doi: 10.3390/cimb44050124
|
| 121 |
Kenneth Cusi. A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. Liver International 2020; 40(S1): 82 doi: 10.1111/liv.14350
|
| 122 |
William P. Esler, Kendra K. Bence. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology 2019; 8(2): 247 doi: 10.1016/j.jcmgh.2019.04.007
|
| 123 |
Shivaram Prasad Singh, Reshu Khandelwal, Anuradha Supun Dassanayake. Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist. Euroasian Journal of Hepato-Gastroenterology 2022; 12(S1): S37 doi: 10.5005/jp-journals-10018-1376
|